Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in Major Depressive Disorder
NCT02969876Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vortioxetine in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Started Aug 2017; status: terminated.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02969876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969876.